Filtern
Volltext vorhanden
- ja (57)
Gehört zur Bibliographie
- ja (57)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (57)
Schlagworte
- colorectal cancer (7)
- inflammatory bowel disease (3)
- CRC (2)
- Crohn's disease (2)
- Germany (2)
- Rectal cancer (2)
- antimicrobial stewardship (2)
- chemotherapy (2)
- complication (2)
- endoluminal (2)
Institut
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (57)
- Theodor-Boveri-Institut für Biowissenschaften (21)
- Comprehensive Cancer Center Mainfranken (13)
- Medizinische Klinik und Poliklinik II (10)
- Medizinische Klinik und Poliklinik I (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Pathologisches Institut (4)
- Institut für Anatomie und Zellbiologie (3)
- Kinderklinik und Poliklinik (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
Background: We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. Methods: One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test. Results: Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001]. Conclusion: A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.